Chemomab Therapeutics (CMMB) Price to Book (2021 - 2026)

Chemomab Therapeutics (CMMB) has reported Price to Book for 6 consecutive years, with 1.34 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Price to Book fell 40.51% year-over-year to 1.34; the trailing twelve-month figure through Jun 2026 stood at 1.34 (down 40.51% YoY), and the FY2025 full-year result was 0.96, down 61.84% from the prior year.
• Price to Book grew to 1.34 in Q2 2026 per CMMB's latest filing, from 1.06 in the prior quarter.
• Across five years, Price to Book topped out at 2.52 in Q4 2024 and bottomed at 0.35 in Q4 2023.
• Historically, Price to Book has averaged 1.1 across 5 years, with a median of 0.99 in 2025.
• The sharpest annual moves came in 2022 and 2024: Price to Book slumped 76.55% in 2022, then jumped 615.13% in 2024.
• Over 5 years, Price to Book stood at 1.03 in 2022, then tumbled by 65.69% to 0.35 in 2023, then soared by 615.13% to 2.52 in 2024, then plunged by 61.84% to 0.96 in 2025, then jumped by 39.43% to 1.34 in 2026.
• According to Business Quant data, Price to Book over the past three periods registered 1.34, 1.06, and 0.96 for Q2 2026, Q1 2026, and Q4 2025 respectively.